PARP1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, our data suggest that the combinatory usage of TKIs with the ATP synthase inhibitor 8-Cl-Ado or the PARP-inhibitor olaparib are promising therapeutic approaches for future clinical studies on CML patients.